The originally planned efficacy analysis over @ weeks was not performed due to limited data at later time points , but there was evidence that telcagepant resulted in a larger reduction from baseline than placebo for mean monthly headache days ( month @ : @ mg = -@ , @ mg = -@ , placebo = -@ ; p < @ ) and migraine/probable migraine days ( month @ : @ mg = -@ , @ mg = -@ , placebo = -@ ; p < @ ) .